William F. Feehery | Source | CEO at Certara
William F. Feehery
Dr. Feehery joined Certara in June, 2019 as CEO. Dr. Feehery joins Certara from DuPont, where he served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business that experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets.
-
We are pleased to welcome Pinnacle 21’s talented team to Certara. With Pinnacle 21’s software for high-quality clinical data standardization, we can together provide a broader portfolio of industry-leading software and technology-driven services to our customers worldwide.
17 January 2022 -
It is a privilege to continue providing software that global regulatory agencies can rely on to inform their reviews of regulatory submissions. We are pleased that more scientists at the FDA are using our biosimulation software to support the development of safe and effective medicines.
17 January 2022 -
We recognize the tremendous growth of China’s biopharmaceutical industry and are thrilled to have a direct presence in China so that we can fully support our rapidly growing Chinese customer base. Certara’s extensive experience in biosimulation and our partnerships with top global biopharmaceutical companies will help foster innovation in China, accelerate time-to-market for our customers, and most importantly, improve patient outcomes.
22 January 2021
-
22 January 2021article
Certara to Open New Office in ChinaThe new office will provide the company with opportunities to collaborate more efficiently with customers in the Chinese biopharmaceutical industry. - 17 January 2022
-
17 January 2022articleCertara Completes Acquisition of Pinnacle 21Complementary technologies accelerate and help assure success in the drug development processPRINCETON, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness. At closing, equity holders of Pinnacle 21 received approximately $250 million in cash
-
Certara
CEO